New research challenges fears of quick weight regain after stopping GLP-1 drugs like Ozempic and Wegovy. Real-world data reveals many patients sustain their losses. Experts say durability is possible without lifelong treatment.
New research suggests that many people who stop using GLP-1 drugs like Ozempic maintain their weight loss, countering previous studies.
Many patients using highly effective GLP-1 drugs may not regain lost weight quickly when they stop treatment. This comes from an analysis of real-world data addressing a key concern about these therapies.
Track your medication journey
Join thousands using Shotlee to track GLP-1 medications.
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
The data contradicts findings from Novo Nordisk's clinical trials, which warned that many patients regain weight soon after interrupting treatment.
Obesity specialists have questioned whether people need these medicines for years to keep benefits.
"The implication of our real-world evidence is not that rebound risk is negligible, but rather that durability is achievable in routine care," said Nference chief scientific officer Venky Soundararajan.
Original source: South China Morning Post
View original article →Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.
Novo Nordisk's Ozempic pioneered the GLP-1 revolution, tripling sales to 309 billion DKK in eight years. Yet shares have cratered 60% due to Eli Lilly's Mounjaro gains, trial disappointments, and looming generics. Discover the booming market's challenges and opportunities.
Novo Nordisk is dramatically reducing prices for its blockbuster GLP-1 drugs, slashing Wegovy by 50% and Ozempic by 35% to $675 per month starting in January 2027. This move addresses calls for affordability from patients and payers facing high-deductible plans. Amid fierce competition from Eli Lilly's Mounjaro and Zepbound, these cuts could broaden access to these transformative medications.
